Topas already has two important collaborations in place and is actively pursuing additional partnerships.
In August 2017, Topas signed a multi-year agreement with Eli Lilly and Company (Lilly) to collaborate in the field of antigen-specific tolerance induction with an initial focus on external antigens thought to induce inflammation and/or autoimmune disease. Topas is responsible for conducting pre-clinical proof-of-principle studies in collaboration with Lilly to generate drug candidates. Under the terms of the agreement, Lilly has an option for all candidates produced under the collaboration for in-licensing and further development. Topas will receive R&D funding and participate in the future success of any compounds in-licensed by Lilly.
Topas also has a co-development program with Evotec to treat Type 1 diabetes, which is currently in proof-of-concept pre-clinical studies.